Skip to content

Geron GERN Accounts Payable

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.23B+5.8%
Incyte logo
IncyteINCY
$228.62M+16.9%
Immunome logo
ImmunomeIMNM
$5.53M-39.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$10.84M+7.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$39M+77.3%
Celcuity logo
CelcuityCELC
$10.45M+5.3%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's accounts payable?
Geron (GERN) reported accounts payable of $12.72M in Q1 2026.
How has Geron's accounts payable changed year-over-year?
Geron's accounts payable increased by 58.4% year-over-year, from $8.03M to $12.72M.
What is the long-term trend for Geron's accounts payable?
Over 5 years (2020 to 2025), Geron's accounts payable has grown at a 10.2% compound annual growth rate (CAGR), from $6.92M to $11.26M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.